Table 7.
Relationship between UGT1A1 polymorphisms and efficacy of patients treated with IP (n = 30)
| Genotype | n | RR (%) | P |
|---|---|---|---|
| UGT1A1*28 | 0.628 | ||
| TA6/6 | 20 | 14 (70.0) | |
| TA6/7 | 7 | 5 (71.4) | |
| TA7/7 | 3 | 2 (66.7) | |
| UGT1A1*6 | 0.352 | ||
| G/G | 21 | 14 (66.7) | |
| A/G | 8 | 6 (75.0) | |
| A/A | 1 | 1 (100.0) | |
| UGT1A1*6 and UGT1A1*28 | 0.336 | ||
| Wild-type | 12 | 8 (66.7) | |
| Single mutation | 13 | 10 (76.9) | |
| Double mutation | 4 | 3 (75.0) |
UGT1A1*28: TA6/6, wild-type; TA6/7, heterozygous; TA7/7, homozygous; UGT1A1 *6: GG, wild-type; GA, heterozygous; AA, homozygous. IP, irinotecan plus cisplatin; RR, response rate; UGT1A1, uridine diphosphate glucuronosyltransferase.